drugset
drugset / Trial / NCT03687684

Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects

NCT03687684 ↗

Phase 1 Completed 40 enrolled Neurocrine Biosciences Takeda · collab
RandomizedSequentialTriple-blindOther

Summary

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-831 when administered as single or multiple oral doses in healthy adult Asian participants.

Timeline

Start
2018-10-09
Primary completion
2019-06-09
Completion
2019-06-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Luvadaxistat Small molecule 50 mg Oral
Subject Luvadaxistat Small molecule 100 mg Oral
Subject Luvadaxistat Small molecule 300 mg Oral
Subject Luvadaxistat Small molecule 600 mg Oral

Indications

No indication recorded.